Travailler pour Lungpacer

Lungpacer développe une solution thérapeutique innovante pour préserver et rétablir l’intégrité et la force du diaphragme chez les patients critiques nécessitant la ventilation mécanique.

Chez Lungpacer, l’union fait la force et c’est pourquoi nous nous engageons à promouvoir et récompenser l’innovation, la passion, l’esprit d’équipe et le courage parmi nos employés. Nous nous engageons à maintenir un environnement de travail axé sur l’esprit d’équipe où les capacités et les succès des individus sont reconnus et leur carrière est soutenue. Nous n’engageons que les meilleurs: ceux qui font preuve d’une forte motivation et d’un véritable esprit d’équipe et dont nous savons qu’ils prendront les bonnes décisions pour atteindre nos objectifs. Chez nous, on peut travailler dur tout en s’amusant.

Nous offrons un cadre de travail axé sur la collaboration, un programme de salaire et d’avantages sociaux complet et la possibilité de participer à un régime d’options d’achat d’actions.

Aucun poste n'est à pourvoir actuellement chez Lungpacer.

close

Apply Now

Choose File No File Chosen

Entrer en contact

Siège social

Lungpacer Medical Inc.
Suite 130, 601 W Cordova Street
Vancouver, B.C. V6B 1G1
Canada

USA

Lungpacer Medical USA Inc.
260 Sierra Drive, #116
Exton, PA 19341
USA


Emergency Use Indication:

The Lungpacer DPTS has been authorized for emergency use in healthcare settings for treatment of patients on invasive mechanical ventilation who are at high risk of weaning failure, including COVID-19 patients, during the COVID-19 pandemic.


Important Safety and Effectiveness Information:

There are no FDA approved, licensed, or cleared device treatments to assist in weaning patients off of ventilators. Based on bench testing and reported clinical experience, FDA has concluded that the Lungpacer DPTS may be effective at treating patients during COVID-19 by helping wean patients off ventilators in healthcare settings, thereby reducing their risks of prolonged mechanical ventilation and increasing the availability of ventilators during the COVID-19 pandemic.

Lungpacer DPTS treatment is for a maximum of 30 days. Device-related serious adverse events reported in clinical trials were single events of pneumothorax and mucus plug liberation.

The LIVE Catheter component of the Lungpacer system has not been evaluated for safety when used with cardiac pacemakers or defibrillators and should be removed prior to Magnetic Resonance (MR) imaging. Duration: The Lungpacer DPTS is available under an Emergency Use Authorization for the duration of the COVID-19 pandemic.

Emergency Use Instructions for Use, Fact Sheet for Healthcare Providers, and Fact Sheet for Patients are available at: http://lungpacer.com/emergency-use-authorization.

For more information visit https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations.



Emergency Use Authorization Information:

This Diaphragmatic Pacing Stimulator has not been FDA cleared or approved.

This Diaphragmatic Pacing Stimulator has been authorized by FDA under an Emergency Use Authorization (EUA).

This Diaphragmatic Pacing Stimulator is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of Diaphragmatic Pacing Stimulator Systems under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.